These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 6986939)

  • 1. Clomipramine and exposure for obsessive-compulsive rituals: i.
    Marks IM; Stern RS; Mawson D; Cobb J; McDonald R
    Br J Psychiatry; 1980 Jan; 136():1-25. PubMed ID: 6986939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clomipramine and exposure for chronic obsessive-compulsive rituals: III. Two year follow-up and further findings.
    Mawson D; Marks IM; Ramm L
    Br J Psychiatry; 1982 Jan; 140():11-8. PubMed ID: 7037100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clomipramine, self-exposure and therapist-aided exposure for obsessive-compulsive rituals.
    Marks IM; Lelliott P; Basoglu M; Noshirvani H; Monteiro W; Cohen D; Kasvikis Y
    Br J Psychiatry; 1988 Apr; 152():522-34. PubMed ID: 3167404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Six-year follow-up after exposure and clomipramine therapy for obsessive compulsive disorder.
    O'Sullivan G; Noshirvani H; Marks I; Monteiro W; Lelliott P
    J Clin Psychiatry; 1991 Apr; 52(4):150-5. PubMed ID: 2016246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of behavioral psychotherapy, I: Obsessive-compulsive disorders.
    Marks IM
    Am J Psychiatry; 1981 May; 138(5):584-92. PubMed ID: 7015882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clomipramine in obsessive-compulsive ritualisers treated with exposure therapy: relations between dose, plasma levels, outcome and side effects.
    Kasvikis Y; Marks IM
    Psychopharmacology (Berl); 1988; 95(1):113-8. PubMed ID: 3133689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obsessive-compulsive beliefs and treatment outcome.
    Lelliott PT; Noshirvani HF; Başoğlu M; Marks IM; Monteiro WO
    Psychol Med; 1988 Aug; 18(3):697-702. PubMed ID: 2903513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder.
    Foa EB; Liebowitz MR; Kozak MJ; Davies S; Campeas R; Franklin ME; Huppert JD; Kjernisted K; Rowan V; Schmidt AB; Simpson HB; Tu X
    Am J Psychiatry; 2005 Jan; 162(1):151-61. PubMed ID: 15625214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clomipramine and exposure for compulsive rituals: II. Plasma levels, side effects and outcome.
    Stern RS; Marks IM; Mawson D; Luscombe DK
    Br J Psychiatry; 1980 Feb; 136():161-6. PubMed ID: 7370482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients.
    Greist JH; Jefferson JW; Rosenfeld R; Gutzmann LD; March JS; Barklage NE
    J Clin Psychiatry; 1990 Jul; 51(7):292-7. PubMed ID: 2195006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline.
    Insel TR; Murphy DL; Cohen RM; Alterman I; Kilts C; Linnoila M
    Arch Gen Psychiatry; 1983 Jun; 40(6):605-12. PubMed ID: 6342562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clomipramine (Anafranil) and behaviour therapy in obsessive-compulsive and phobic disorders.
    Amin MM; Ban TA; Pecknold JC; Klingner A
    J Int Med Res; 1977; 5 Suppl 5():33-7. PubMed ID: 340305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of chronic obsessive-compulsive neurosis by in-vivo exposure. A two-year follow-up and issues in treatment.
    Marks IM; Hodgson R; Rachman S
    Br J Psychiatry; 1975 Oct; 127():349-64. PubMed ID: 241455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary results from a multicenter trial of clomipramine in obsessive-compulsive disorder.
    DeVeaugh-Geiss J; Landau P; Katz R
    Psychopharmacol Bull; 1989; 25(1):36-40. PubMed ID: 2672070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clomipramine in obsessive-compulsive disorder: a review.
    Ananth J
    Psychosomatics; 1983 Aug; 24(8):723-7. PubMed ID: 6356210
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.
    Piccinelli M; Pini S; Bellantuono C; Wilkinson G
    Br J Psychiatry; 1995 Apr; 166(4):424-43. PubMed ID: 7795913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder.
    Pato MT; Zohar-Kadouch R; Zohar J; Murphy DL
    Am J Psychiatry; 1988 Dec; 145(12):1521-5. PubMed ID: 3057923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clomipramine, fluoxetine, and behavior therapy in the treatment of obsessive-compulsive disorder: a meta-analysis.
    Cox BJ; Swinson RP; Morrison B; Lee PS
    J Behav Ther Exp Psychiatry; 1993 Jun; 24(2):149-53. PubMed ID: 8263222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symptoms and physiologic manifestations in obsessive compulsive patients before and after treatment with clomipramine.
    Hoehn-Saric R; McLeod DR; Zimmerli WD; Hipsley PA
    J Clin Psychiatry; 1993 Jul; 54(7):272-6. PubMed ID: 8335655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Worldwide use of clomipramine.
    Trimble MR
    J Clin Psychiatry; 1990 Aug; 51 Suppl():51-4; discussion 55-8. PubMed ID: 2199435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.